View in EDS HTML Full Text PDF Full Text

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.

Saved in:
Bibliographic Details
Title: Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.
Authors: Reardon, David A.1 (AUTHOR) david_reardon@dfci.harvard.edu, Kim, Tae Min2 (AUTHOR), Frenel, Jean‐Sebastien3 (AUTHOR), Simonelli, Matteo4,5 (AUTHOR), Lopez, Juanita6 (AUTHOR), Subramaniam, Deepa S.7 (AUTHOR), Siu, Lillian L.8 (AUTHOR), Wang, Hui9 (AUTHOR), Krishnan, Suba10 (AUTHOR), Stein, Karen10 (AUTHOR), Massard, Christophe11 (AUTHOR)
Source: Cancer (0008543X). May2021, Vol. 127 Issue 10, p1620-1629. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:0008543X
DOI:10.1002/cncr.33378